CRISPR Therapeutics President & Chairman Novak to resign Sept 15; CEO Kulkarni to become Chairman

CRISPR Therapeutics AG

Rodger Novak resigns as President and Chairman, effective September 15, 2023; no dispute or disagreement cited.
Samarth Kulkarni, Ph.D., CEO, appointed Chairman of the Board effective same date; will continue as CEO.
Novak co-founded CRISPR nearly 10 years ago, was instrumental in key collaborations and exa-cel development.
Kulkarni's compensation arrangement remains unchanged; Board thanks Novak for his leadership.
CRISPR's exa-cel for sickle cell disease and beta thalassemia is under regulatory review for potential first CRISPR-based medicine approval.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rodger Novak

President and Chairman

CRSP · CRISPR Therapeutics AG

Effective: 2023-09-15
Filed: September 7, 2023, 7:59 PM ET

On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rodger Novak resigned as President and Chairman at CRISPR Therapeutics AG.

Action: resigned
Role: President and Chairman

Exact text from the filing

On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”).

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-046889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.